Full-Time

Senior Director

Clinical Affairs

Updated on 8/1/2026

Deadline 7/16/27
Sysmex

Sysmex

1,001-5,000 employees

Manufactures automated hematology analyzers and diagnostics

Compensation Overview

$210k - $330k/yr

+ Annual incentive bonus

Mundelein, IL, USA + 1 more

More locations: Lincolnshire, IL, USA

In Person

Travel required up to 35% of the time.

Category
Biology & Biotech (1)
Required Skills
Microsoft Office
FDA Regulations
Microsoft Outlook

Get referred to Sysmex

See people who can refer or advise you

Requirements
  • A Master's degree is required.
  • A minimum of 15+ years of clinical research experience is required, including at least 8 years leading clinical projects and experience in the Armed Forces.
  • Experience in all aspects of preclinical and clinical study evaluations is required.
  • Technical laboratory instrument expertise or experience is required.
  • In-depth knowledge of regulations and industry standards affecting preclinical and clinical studies of in vitro diagnostic products, including Good Clinical Practice and Good Laboratory Practice, is required.
  • Technical expertise in the various aspects of the clinical evaluation process is required.
  • A history of significant contribution to planning and executing clinical strategies in support of product clearance is required.
  • Knowledge of regulations and standards affecting clinical and preclinical studies of Sysmex products is required.
  • English language proficiency is required.
  • Excellent general information technology skills, including Microsoft Office, Microsoft Outlook, and Adobe, and basic statistics are required.
  • The ability to follow guidelines and effectively communicate scientific data in a structured manner is required.
  • The ability to understand and interpret scientific data related to regulatory requirements and strategy and provide knowledge and expertise to guide others is required.
  • Strong interpersonal skills and the ability to interface effectively with all levels of staff and management, internally and externally, are required.
  • Excellent organizational skills and attention to detail are required.
  • The ability to manage multiple priorities is required.
  • Satisfaction of Sysmex customer credentialing requirements, generally including proof of current vaccinations for measles, mumps, rubella, varicella, and COVID-19, is required.
Responsibilities
  • Develop, coordinate, and execute the clinical strategy for new and modified Sysmex in vitro diagnostic products.
  • Understand device operating principles and develop preclinical and clinical evaluation plans, including study protocols.
  • Determine study documentation requirements and generate final reports and sections of FDA applications.
  • Direct and comply with all policies, established procedures, and regulations related to studies.
  • Maintain professional, product, and market expertise through independent reading, networking, and training.
  • Execute clinical evaluations in alignment with business goals and objectives.
  • Establish, manage, and achieve project milestones with internal staff, other departments, study investigators, and research coordinators.
  • Ensure associates are accountable for timely development of clinical trial documentation, including instructions for use, case report forms, case report form guidelines, informed consent, monitoring plans and reports, study protocols, and other clinical or regulatory documentation.
  • Mentor and support staff in clinical and regulatory documentation activities.
  • Oversee project progress and adherence to timelines, including enrollment, clinical supplies, and data management and delivery.
  • Identify issues that may affect the overall project plan, initiate contingency plans, and communicate with leadership as appropriate.
  • Direct the operations of the Sysmex RACA Laboratory in alignment with the Laboratory Manager.
  • Function as the Principal Investigator for institutional review board-approved studies.
  • Establish and maintain relationships with outside institutions required for evaluations, including recruiting investigational sites and negotiating and maintaining budgets and contracts.
  • Contribute to clinical sections of regulatory submissions.
  • Generate and author final reports supporting regulatory filings.
Desired Qualifications
  • A PhD degree is desired.
  • A medical or science background is highly desired.
  • Laboratory and/or laboratory information system computer skills would be a plus.

Sysmex designs and sells instruments and reagents for in-vitro diagnostics, with a focus on automated hematology analyzers that count and evaluate blood cells, enabling clinical decision-making. Over time, it expanded into genetics through the acquisition of Oxford Gene Technology and into rapid antimicrobial testing with Astrego, broadening its diagnostic portfolio. The company differentiates itself by growing through acquisitions to build a diverse, global product line and by maintaining a strong brand presence in workflows for hematology, genetics, and infectious disease testing across more than 190 countries. Its goal is to provide essential, reliable diagnostic tools that support healthcare worldwide, helping clinicians diagnose and treat diseases faster and more accurately.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Kobe, Japan

Founded

1968

Get referred to Sysmex

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • XR-Series targets high-complexity labs needing faster throughput and workflow efficiency.
  • 3D scattergram analytics and WPC channel strengthen premium feature upsell.
  • Installed-base familiarity should ease XN-Series customer upgrades and preserve reagent pull-through.

What critics are saying

  • Roche, Abbott, Siemens, and Beckman Coulter pressure hematology placements.
  • XR-Series execution misses would damage credibility and slow conversions.
  • Heavy hematology dependence leaves Sysmex exposed to single-vendor hospital standardization losses.

What makes Sysmex unique

  • Founded in Kobe in 1968 as TOA Medical Electronics with eight employees.
  • Sysmex brand launched in 1978, then corporate renaming followed in 1998.
  • Deep hematology focus, with global diagnostics across over 190 countries.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Parental Leave

Bereavement Leave

401(k) Retirement Plan

401(k) Company Match

Annual Incentive Bonus

Growth & Insights and Company News

Headcount

6 month growth

32%

1 year growth

32%

2 year growth

32%
Sysmex Corporation
Mar 5th, 2026
Sysmex Acquires Additional Shares in RIKEN GENESIS and Converts Company to a Subsidiary

This section provides Sysmex’s most recent news releases related to IR information, products and support, research and development, corporate information and other notifications.

Sysmex Corporation
Jan 22nd, 2026
Launch of "CN(TM)-9000 Automated Hemostasis Solution" for Large-Scale Laboratories in North America - Supporting the Optimization of Laboratory Workflow - (Sysmex America)

Launch of "CN(TM)-9000 Automated Hemostasis Solution" for large-scale laboratories in North America - supporting the optimization of laboratory workflow - (Sysmex America). Sysmex America, Inc., a Sysmex Group company, has launched the "CN(TM)-9000 Automated Hemostasis Solution" as a new addition to the CN-Series for hemostasis testing in the North American market. This product supports further automation and increased efficiency in testing operations at large hospitals and testing centers with high test volumes. In addition to standalone operation, the CN(TM)-9000 is compatible with Total Laboratory Automation (TLA) lines, enabling flexible system configurations tailored to the size and operational needs of each laboratory. For further details, please refer to Sysmex America's press release. Going forward, Sysmex will continue to work to further enhance the value of hemostasis through product development and services that address the increasingly varied and sophisticated needs of medical settings, thereby contributing to improved patient outcomes. * The purpose of this news is to communicate its business activities to its stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising, or medical advice. The information contained in this press release is current as of the date of the announcement but may be subject to change without prior notice.

LabX Media Group
Jan 21st, 2026
Sysmex America Launches CN-9000 to Streamline Hemostasis Workflow in Busy Clinical Labs

Sysmex America launches CN-9000 to streamline hemostasis workflow in busy clinical labs. Designed for high-throughput labs, the CN-9000 boosts efficiency, reduces manual handling, and integrates seamlessly with lab automation systems. Listen with Speechify Sysmex America, Inc., a leader in diagnostic solutions, has announced the launch of the CN-9000 Automated Hemostasis Solution, the latest innovation in its CN-Series. This new system is engineered to help clinical laboratories of all sizes - especially high-volume ones - optimize workflow and keep up with increasing testing demands. With the ability to process up to 1,000 samples per hour, the CN-9000 supports continuous sample loading, automated rerun/reflex testing, and seamless connectivity to compatible total laboratory automation (TLA) lines. Features like closed-tube sampling and Preanalytical Sample Integrity (PSI(TM) checks enhance safety while reducing errors and manual labor. Key features of the CN-9000. * High-throughput processing: up to 1,000 samples/hour * Automated rerun/reflex testing * Closed-tube sampling and PSI(TM) checks * Modular setup with support for CN-3000/CN-6000 analyzers * Optional integration with Sysmex TS-10(TM) Tube Sorter and Archiver * Flexible layout with turn modules for space-saving configurations "Sysmex America's hemostasis solutions help labs keep up with growing testing demands," said Dan Zortman, CEO of Sysmex America. "With the CN-Series, CN-9000, we're giving labs a reliable, high-throughput, walkaway solution that makes daily operations easier and more efficient." Supporting smarter, scalable lab operations. The CN-9000's modular design allows for integration of up to three analyzers and multiple accessories, making it highly adaptable for both current and future lab needs. With intelligent tube routing and minimized manual intervention, the CN-9000 supports lab managers in achieving consistent, scalable, and efficient testing operations. For more information about the CN-9000 and Sysmex America's full hemostasis product line, visit www.sysmex.com. * craig bradley craig bradley bsc (hons), msc, has a strong academic background in human biology, cardiovascular sciences, and biomedical engineering. Since 2025, he has been working with labx media group as a SEO editor. Craig can be reached at [email protected]. View full profile.

Sysmex Corporation
Jan 19th, 2026
Sysmex Makes Megakaryon Corporation into a Subsidiary, Aiming at Accelerating Efforts in the Field of Regenerative and Cellular Medicine

Sysmex Corporation’s corporate philosophy defines its mission as “Shaping the advancement of healthcare.” On that basis, we provide diagnostic instruments, reagents and software throughout the world.

Sysmex Corporation
Aug 27th, 2025
Sysmex America Recognized with Brandon Hall Group Bronze Award for Leadership Development

Chicago - August 27, 2025 - Sysmex America, Inc., a leading diagnostic solutions company offering hematology, hemostasis, urinalysis, flow cytometry and informatic solutions, has been recognized with a Brandon Hall Group(TM) Bronze award for excellence in the Best Development Program for Frontline Leaders category for the Considering the Shift Program offered through Sysmex University.